skip to main content

DOE PAGESDOE PAGES

Title: Metformin Treatment Inhibits Motility and Invasion of Glioblastoma Cancer Cells

Glioblastoma multiforme (GBM) is one of the most common and deadliest cancers of the central nervous system (CNS). GBMs high ability to infiltrate healthy brain tissues makes it difficult to remove surgically and account for its fatal outcomes. To improve the chances of survival, it is critical to screen for GBM-targeted anticancer agents with anti-invasive and antimigratory potential. Metformin, a commonly used drug for the treatment of diabetes, has recently emerged as a promising anticancer molecule. This prompted us, to investigate the anticancer potential of metformin against GBMs, specifically its effects on cell motility and invasion. The results show a significant decrease in the survival of SF268 cancer cells in response to treatment with metformin. Furthermore, metformin’s efficiency in inhibiting 2D cell motility and cell invasion in addition to increasing cellular adhesion was also demonstrated in SF268 and U87 cells. Finally, AKT inactivation by downregulation of the phosphorylation level upon metformin treatment was also evidenced. In conclusion, this study provides insights into the anti-invasive antimetastatic potential of metformin as well as its underlying mechanism of action.
Authors:
ORCiD logo [1] ; ORCiD logo [1] ;  [1] ;  [1] ;  [1] ; ORCiD logo [1] ; ORCiD logo [2] ; ORCiD logo [1]
  1. Department of Natural Sciences, School of Arts and Sciences, Lebanese American University, Beirut, Lebanon
  2. Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, El-Kurah, Lebanon
Publication Date:
Type:
Published Article
Journal Name:
Analytical Cellular Pathology
Additional Journal Information:
Journal Name: Analytical Cellular Pathology Journal Volume: 2018; Journal ID: ISSN 2210-7177
Publisher:
Hindawi Publishing Corporation
Sponsoring Org:
USDOE Office of Electricity Delivery and Energy Reliability (OE), Power Systems Engineering Research and Development (R&D) (OE-10)
Country of Publication:
Country unknown/Code not available
Language:
English
OSTI Identifier:
1457218

Al Hassan, Marwa, Fakhoury, Isabelle, El Masri, Zeinab, Ghazale, Noura, Dennaoui, Rayane, El Atat, Oula, Kanaan, Amjad, and El-Sibai, Mirvat. Metformin Treatment Inhibits Motility and Invasion of Glioblastoma Cancer Cells. Country unknown/Code not available: N. p., Web. doi:10.1155/2018/5917470.
Al Hassan, Marwa, Fakhoury, Isabelle, El Masri, Zeinab, Ghazale, Noura, Dennaoui, Rayane, El Atat, Oula, Kanaan, Amjad, & El-Sibai, Mirvat. Metformin Treatment Inhibits Motility and Invasion of Glioblastoma Cancer Cells. Country unknown/Code not available. doi:10.1155/2018/5917470.
Al Hassan, Marwa, Fakhoury, Isabelle, El Masri, Zeinab, Ghazale, Noura, Dennaoui, Rayane, El Atat, Oula, Kanaan, Amjad, and El-Sibai, Mirvat. 2018. "Metformin Treatment Inhibits Motility and Invasion of Glioblastoma Cancer Cells". Country unknown/Code not available. doi:10.1155/2018/5917470.
@article{osti_1457218,
title = {Metformin Treatment Inhibits Motility and Invasion of Glioblastoma Cancer Cells},
author = {Al Hassan, Marwa and Fakhoury, Isabelle and El Masri, Zeinab and Ghazale, Noura and Dennaoui, Rayane and El Atat, Oula and Kanaan, Amjad and El-Sibai, Mirvat},
abstractNote = {Glioblastoma multiforme (GBM) is one of the most common and deadliest cancers of the central nervous system (CNS). GBMs high ability to infiltrate healthy brain tissues makes it difficult to remove surgically and account for its fatal outcomes. To improve the chances of survival, it is critical to screen for GBM-targeted anticancer agents with anti-invasive and antimigratory potential. Metformin, a commonly used drug for the treatment of diabetes, has recently emerged as a promising anticancer molecule. This prompted us, to investigate the anticancer potential of metformin against GBMs, specifically its effects on cell motility and invasion. The results show a significant decrease in the survival of SF268 cancer cells in response to treatment with metformin. Furthermore, metformin’s efficiency in inhibiting 2D cell motility and cell invasion in addition to increasing cellular adhesion was also demonstrated in SF268 and U87 cells. Finally, AKT inactivation by downregulation of the phosphorylation level upon metformin treatment was also evidenced. In conclusion, this study provides insights into the anti-invasive antimetastatic potential of metformin as well as its underlying mechanism of action.},
doi = {10.1155/2018/5917470},
journal = {Analytical Cellular Pathology},
number = ,
volume = 2018,
place = {Country unknown/Code not available},
year = {2018},
month = {6}
}